Novo Nordisk reported DKK121.79B in Loan Capital for its fiscal quarter ending in June of 2026.





Loan Capital Change Date
Bausch Health Companies USD 19.88B 20M Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Eli Lilly USD 47.86B 8.49B Jun/2026
GlaxoSmithKline GBP 13.95B 65M Jun/2026
Merck USD 51.08B 4.41B Jun/2026
Novartis USD 37.49B 42M Jun/2026
Novo Nordisk DKK 121.79B 2.62B Jun/2026
Novo Nordisk DKK 18.61B 100.56B Jun/2026
Pacira USD 363.12M 4.53M Jun/2026
Sanofi EUR 14.65B 806M Jun/2026
Supernus Pharmaceuticals USD 400.38M 21.13M Mar/2022